Compare Abeona Therapeutics Inc (ABEO) vs Nebius Group NV (NBIS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Nebius Group NV — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Nebius Group NV trades at $204.94 (market cap $49.56B). The key difference: Nebius Group NV is far larger — about 132.8× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Nebius Group NV nearer its low. Which is the better fit depends on your goals.
| ABEO | NBIS | |
|---|---|---|
Market Cap | $373.32M | $49.56B |
Sector | Health | Technology |
52-Week High | $7.23 | $286.69 |
52-Week Low | $4.17 | $44.30 |
Enterprise Value | $228.22M | $49.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
NBIS trades at $213.02, down 1.21% with bearish technical signals despite strong analyst support. The stock shows premium valuations (P/E 82.25, P/S 64.41) but impressive profitability (93.09% net margin) and robust revenue growth projections from $530M to $878M. Recent volatility stems from Meta's potential cloud competition, though news highlights Nebius's AI infrastructure strength and institutional buying interest.
Outlook remains positive with 87.5% analyst buy ratings and $233.13 consensus target, but high valuation and competitive risks from tech giants temper near-term upside. Cash flow trends show aggressive expansion funding, while earnings beats/misses reflect execution volatility in a high-growth sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Nebius Group NV
Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →
